Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020-论文-万方医学网

Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020

导出原文传递

翻译打印收藏纠错

作者： Outterson, Kevin ^[1] ; Orubu, Ebiowei S. F. ^[2] ; Rex, John ^[3] ; Ardal, Christine ^[4] ; Zaman, Muhammad H. ^[5]

作者单位： Sch Law,Boston Univ ^[1] Social Innovat Drug Resistance Program,Boston Univ ^[2] F2G Ltd ^[3] Antimicrobial Resistance Ctr,Norwegian Inst Publ Hlth ^[4] Dept Biomed Engn,Boston Univ ^[5]

关键词 access antibacterial approval commercial launch

发布时间 2022-07-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020

相似文献

相关期刊

检索历史清除